Lilly manufacturing reinspections

FDA has begun reinspecting Lilly's manufacturing facilities for the antidepressant Cymbalta and intramuscular antipsychotic Zyprexa IM. "The reinspections began in early May 2003," Lilly says in its 10-Q filed with the Securities & Exchange Commission May 8. FDA arrived in Indianapolis May 5. The company told investors April 22 that Cymbalta's (duloxetine) fill-finish facility was ready for reinspection, while Zyprexa IM (olanzapine) would be ready for reinspection later this year (1"The Pink Sheet" April 28, p. 31)...